Pacira BioSciences Inc - Company Profile
Powered by 
All the data and insights you need on Pacira BioSciences Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Pacira BioSciences Inc Strategy Report
- Understand Pacira BioSciences Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Pacira BioSciences Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Pacira BioSciences Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 25 Feb 2021 | Lorem |
| Heron’s HTX-011 has experts dubious about Phase III study hitting 72-hour pain relief primary endpoint | 22 Feb 2018 | Shuan Sim |
| Durect’s Posimir for post-op pain may have uptake challenged by low clinical significance and underwhelming similar product on market – experts | 05 Oct 2017 | Shuan Sim, Jennifer C. Smith-Parker |
| Durect’s Posimir has experts questioning its instillation administration's ability to demonstrate meaningful Phase III efficacy and safety in post-op pain | 29 Sep 2017 | Jennifer C. Smith-Parker |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward